Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...
In March of this year, ACTO co-founder and CEO Parth Khanna wrote a piece for Pharmaceutical Executive discussing an area where he sees AI making a major impact. According to him, digital health ...
Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research ...
There is a myth in our industry that when an RBQM implementation fails to deliver the cause must be technical. It was the ...
GSK intends to move its mRNA seasonal influenza vaccine candidate to a Phase III efficacy trial starting in September. The move is based on presented positive Phase II data for it ...
Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research environments.
Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer ...
The Trump administration adds nine midsize pharmaceutical companies, including Teva, UCB, Astellas, and BeOne Medicines to ...
Nate Hill, co-founder & CEO of Strive Pharmacy, argues that a Category one designation for peptides would give physicians a trusted, regulated channel they currently lack. Nate Hill, Co-Founder & CEO ...
Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...
Taken together, Hill's response suggests that restricting access through legitimate compounding channels, without addressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results